Ardelyx announced on April 29, 2025, the appointment of Merdad Parsey, M.D., Ph.D., to its board of directors. Dr. Parsey brings over 25 years of experience in the pharmaceutical and biopharma industries, including significant leadership roles in clinical development.
Dr. Parsey most recently served as Chief Medical Officer at Gilead Sciences, Inc. from 2019 until his retirement in 2025, and previously held senior roles at Genentech, Inc. and 3-V Biosciences. His extensive expertise in research, early development, and clinical strategy is expected to be crucial for Ardelyx's pipeline expansion and growth initiatives.
This appointment strengthens Ardelyx's governance and strategic capabilities, aligning with the company's vision to accelerate the growth of its existing commercial products and build a robust pipeline of innovative medicines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.